US 12,447,146 B2
Topical composition comprising tacrolimus
Nigel Crutchley, Letherhead (GB)
Assigned to MC2 Therapeutics Limited, Letherhead (GB)
Filed by MC2 Therapeutics Limited, Letherhead (GB)
Filed on May 23, 2022, as Appl. No. 17/750,836.
Application 17/750,836 is a continuation of application No. 16/090,993, granted, now 11,458,125, previously published as PCT/EP2017/057897, filed on Apr. 3, 2017.
Claims priority of application No. 16163724 (EP), filed on Apr. 4, 2016.
Prior Publication US 2022/0273627 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/436 (2006.01); A61K 9/00 (2006.01); A61K 9/107 (2006.01); A61K 47/06 (2006.01); A61K 47/14 (2017.01); A61P 17/06 (2006.01)
CPC A61K 31/436 (2013.01) [A61K 9/0014 (2013.01); A61K 9/107 (2013.01); A61K 47/06 (2013.01); A61K 47/14 (2013.01); A61P 17/06 (2018.01)] 21 Claims
 
1. A composition for topical application comprising:
a first discontinuous phase comprising a first oil and tacrolimus, wherein the first oil comprises diisopropyl adipate;
a second discontinuous phase comprising a second oil, wherein the second oil comprises an oil selected from the group consisting of mineral oil, dimethicone, cyclomethicone, hydrogenated polyisobutane, heptamethylnonane, and mixtures of two or more thereof; and
a continuous aqueous phase;
wherein the first oil is different from the second oil,
wherein the tacrolimus is substantially soluble in the first oil and substantially insoluble in the second oil,
wherein said composition has a total surfactant content of less than 1 wt % by weight of the composition, and
wherein the first discontinuous phase and the second discontinuous are separate discontinuous phases so that the first discontinuous phase is dispersed in the continuous phase and the second discontinuous phase is dispersed in the continuous phase.